Western Regional Blog – BC, YK, AB, NWT and Nunavut
TAKE-HOME MESSAGE This case-control study of postmenopausal women demonstrated that bisphosphonate use for 1 year or more decreased the risk of developing ovarian or endometrial cancer, with or without the concomitant use of statins. The authors concluded that bisphosphonate use may prevent the development of ovarian or endometrial cancer.
OBJECTIVE The use of bisphosphonates has been associated with reduced risk and improved survival of breast and colorectal malignancies. This study was aimed at studying the effects of bisphosphonates on gynecological cancers.
METHODS The Cancer in the Ovary and Uterus Study (CITOUS) is a case-control study of newly diagnosed cases of gynecological malignancies and age/clinic/ethnic-group matched population controls. The use of bisphosphonates prior to, and following, diagnosis was assessed in 424 cases of ovarian and endometrial cancers and 341 controls, all postmenopausal at recruitment, enrolled in Clalit Health Services (CHS), using pharmacy records.
RESULTS The use of bisphosphonates for more than 1year prior to diagnosis was associated with a significantly reduced risk of ovarian cancer (OR=0.49, 95% CI: 0.26-0.93) and endometrial cancer (OR=0.39, 95% CI: 0.24-0.63). The association with endometrial cancer (OR=0.48, 0.27-0.84) remained statistically significant after adjustment for a variety of putative effect modifiers (RR=0.48, 0.26-0.89). The association with ovarian cancer remained significant when adjusted to statin use (0.46, 0.23-0.90) but not for other modifiers (0.58, 0.29-1.18). A strong negative association was found in an adjusted model for the use of either bisphosphonates or statins for more than 1year (0.40, 0.23-0.68).
CONCLUSION The use of bisphosphonates, with or without statins, for more than 1year before diagnosis was associated with reduced risk of endometrial and ovarian cancers.
Gynecol. Oncol 2014 Mar 14;[EPub Ahead of Print], G Rennert, HS Rennert, M Pinchev, O Lavie